Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Gains from Investment Securities (2016 - 2025)

IGC Pharma (IGC) has disclosed Gains from Investment Securities for 14 consecutive years, with -$196000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Gains from Investment Securities fell 86.67% to -$196000.0 in Q4 2023 year-over-year; TTM through Mar 2025 was -$196000.0, a 54.21% increase, with the full-year FY2024 number at -$154000.0, down 294.87% from a year prior.
  • Gains from Investment Securities was -$196000.0 for Q4 2023 at IGC Pharma, down from -$127000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.1 million in Q4 2019 to a low of -$5.0 million in Q1 2021.
  • A 5-year average of -$42538.5 and a median of -$105000.0 in 2022 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 28022.22% in 2021, then skyrocketed 96.98% in 2022.
  • IGC Pharma's Gains from Investment Securities stood at $5.1 million in 2019, then crashed by 76.77% to $1.2 million in 2020, then tumbled by 97.7% to $27000.0 in 2021, then plummeted by 488.89% to -$105000.0 in 2022, then crashed by 86.67% to -$196000.0 in 2023.
  • Per Business Quant, the three most recent readings for IGC's Gains from Investment Securities are -$196000.0 (Q4 2023), -$127000.0 (Q1 2023), and -$105000.0 (Q4 2022).